Description
The global lung stent market was valued at USD 175.8 million in 2025 and is projected to reach USD 331.9 million by 2032, expanding at a CAGR of 9.5% from 2026 to 2032. The market includes airway stents used to restore or maintain patency in obstructed tracheal, bronchial, and laryngeal airways. Growing prevalence of lung cancer, COPD, post-tuberculosis airway stenosis, and other structural airway disorders is creating sustained demand for interventional airway management. Increasing adoption of minimally invasive bronchoscopic procedures is also expanding the use of lung stents across complex airway interventions.
Market growth is being reinforced by advances in stent materials, delivery systems, covered configurations, and customized designs. Self-expandable metallic stents are increasingly suited to flexible-bronchoscopy workflows, while silicone stents remain important where removability and management of benign airway disease are key considerations. Innovations targeting tissue ingrowth, migration, mucus accumulation, and complex airway anatomy are creating opportunities for differentiated products. At the same time, alternative airway therapies, regulatory requirements, and procedure-related complications continue to influence product selection and market adoption.
North America currently represents the largest regional market, supported by advanced interventional pulmonology infrastructure, established reimbursement pathways, and high availability of specialized airway procedures. Asia Pacific is projected to be the fastest-growing region, supported by expanding healthcare infrastructure, increasing access to bronchoscopic interventions, and a growing burden of respiratory diseases.
Key Highlights of the Report
• By product, tracheal stents dominate the global lung stent market, reflecting their extensive use in managing central-airway obstruction, malignant compression, post-intubation stenosis, tracheomalacia, and other complex tracheal conditions.
• Bronchial stents are projected to register the fastest growth among product categories, supported by increasing use of flexible bronchoscopy for managing obstructions involving the main, lobar, and selected segmental bronchi.
• Laryngeal stents represent a specialized segment, with applications across post-surgical, traumatic, congenital, and post-radiation laryngeal stenosis.
• By device type, self-expandable stents dominate the market, owing to their ability to conform to variable airway anatomies and provide continuous radial force following deployment.
• Balloon-expandable stents continue to serve selected clinical applications, particularly where precise placement and controlled expansion are important.
• By material, silicone stents account for the largest market share, supported by their removability and continued clinical relevance in benign airway disease and temporary airway reconstruction.
• Metal stents represent a significant market segment, with nitinol gaining importance because of its flexibility, superelasticity, and compatibility with lower-profile delivery systems.
• Nitinol-based stents are expected to witness strong growth, driven by increasing adoption of self-expandable platforms and their suitability for irregular or dynamically compressed airways.
• Hybrid stents are emerging as an innovation-focused segment, combining structural support with covered configurations designed to reduce tissue ingrowth and address complications associated with long-term airway stenting.
• By patient, the adult segment dominates the global lung stent market, reflecting the higher prevalence of malignant airway obstruction, COPD, and other acquired airway disorders in adults.
• The pediatric segment represents a specialized opportunity, particularly for congenital airway abnormalities, post-infectious stenosis, and complex airway reconstruction requiring precise sizing and specialized device designs.
• By end use, hospitals dominate the market, owing to the availability of advanced bronchoscopy suites, interventional pulmonology expertise, oncology services, imaging capabilities, and post-procedural monitoring infrastructure.
• Ambulatory surgical centers are expected to witness strong growth, supported by increasing adoption of minimally invasive bronchoscopic procedures and improvements in stent delivery systems that can enable selected procedures outside traditional inpatient settings.
• The rising prevalence of lung cancer remains a major market driver, particularly because malignant airway obstruction can require rapid restoration of airway patency.
• COPD and post-tuberculosis airway stenosis are expanding the addressable patient pool, creating demand beyond oncology-focused airway interventions.
• Growing adoption of flexible bronchoscopy is transforming the lung stent market, improving access to selected airway lesions and supporting the use of lower-profile, self-expanding delivery systems.
• Product innovation is increasingly focused on covered, customized, and potentially biodegradable stent technologies, with manufacturers seeking to address tissue ingrowth, migration, secretion management, and complex airway geometries.
• Alternative airway therapies remain a key market restraint, as balloon dilation, laser bronchoscopy, cryotherapy, and endobronchial brachytherapy can eliminate or delay the need for stent implantation in selected patients.
• Regulatory and clinical-evidence requirements can limit market entry for emerging manufacturers, particularly for novel materials and next-generation airway stent designs.
• Stent-related complications, including migration, granulation tissue formation, mucus plugging, and infection, remain important clinical challenges, influencing device selection and encouraging continued product innovation.
• North America dominates the global lung stent market, supported by established interventional pulmonology capabilities and advanced healthcare infrastructure.
• Asia Pacific is expected to register the fastest growth, driven by expanding healthcare infrastructure, improving access to advanced respiratory interventions, and increasing disease burden.
• The competitive landscape is relatively concentrated, with Boston Scientific, COOK GROUP, MERIT MEDICAL, MICRO-TECH ENDOSCOPY, and TaeWoong MEDICAL identified among the leading companies.
Key Company Profiles
• Boston Scientific
• COOK GROUP
• EFER ENDOSCOPY
• MERIT MEDICAL
• mi-Tech
• NOVATECH
• Standard Sci Tech
• STENING
• TaeWoong MEDICAL
• Teleflex
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
